Kalaris Therapeutics (KLRS) Competitors $2.27 -0.01 (-0.44%) As of 08/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsTrendsBuy This Stock KLRS vs. MDWD, AVTE, IPHA, SXTC, ENGN, GNFT, CTMX, EPRX, VTYX, and TVGNShould you be buying Kalaris Therapeutics stock or one of its competitors? The main competitors of Kalaris Therapeutics include MediWound (MDWD), Aerovate Therapeutics (AVTE), Innate Pharma (IPHA), China SXT Pharmaceuticals (SXTC), enGene (ENGN), GENFIT (GNFT), CytomX Therapeutics (CTMX), Eupraxia Pharmaceuticals (EPRX), Ventyx Biosciences (VTYX), and Semper Paratus Acquisition (TVGN). These companies are all part of the "pharmaceutical products" industry. Kalaris Therapeutics vs. Its Competitors MediWound Aerovate Therapeutics Innate Pharma China SXT Pharmaceuticals enGene GENFIT CytomX Therapeutics Eupraxia Pharmaceuticals Ventyx Biosciences Semper Paratus Acquisition Kalaris Therapeutics (NASDAQ:KLRS) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings. Does the media favor KLRS or MDWD? In the previous week, MediWound had 6 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 9 mentions for MediWound and 3 mentions for Kalaris Therapeutics. MediWound's average media sentiment score of -0.12 beat Kalaris Therapeutics' score of -0.38 indicating that MediWound is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediWound 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer KLRS or MDWD? Kalaris Therapeutics presently has a consensus price target of $3.00, indicating a potential upside of 32.16%. MediWound has a consensus price target of $32.25, indicating a potential upside of 73.67%. Given MediWound's stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kalaris Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00MediWound 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, KLRS or MDWD? MediWound has higher revenue and earnings than Kalaris Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalaris TherapeuticsN/AN/A-$58.77MN/AN/AMediWound$20.22M9.93-$30.22M-$2.09-8.89 Is KLRS or MDWD more profitable? Kalaris Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -110.45%. Kalaris Therapeutics' return on equity of -71.15% beat MediWound's return on equity.Company Net Margins Return on Equity Return on Assets Kalaris TherapeuticsN/A -71.15% -61.67% MediWound -110.45%-74.12%-30.92% Which has more volatility & risk, KLRS or MDWD? Kalaris Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Comparatively, MediWound has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500. Do institutionals & insiders believe in KLRS or MDWD? 66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 75.0% of Kalaris Therapeutics shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryMediWound beats Kalaris Therapeutics on 8 of the 13 factors compared between the two stocks. Get Kalaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KLRS vs. The Competition Export to ExcelMetricKalaris TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.64M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2925.74Price / SalesN/A356.37470.61115.79Price / CashN/A43.0338.2159.48Price / Book0.108.608.866.15Net Income-$58.77M-$54.65M$3.25B$265.06M7 Day Performance-14.98%5.86%3.72%2.60%1 Month Performance-5.42%8.86%5.86%2.83%1 Year PerformanceN/A13.33%30.49%25.58% Kalaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KLRSKalaris Therapeutics2.1446 of 5 stars$2.27-0.4%$3.00+32.2%N/A$42.64MN/A0.00110Earnings ReportMDWDMediWound1.5584 of 5 stars$18.53-0.6%$32.25+74.0%+6.3%$200.27M$20.22M-8.8780News CoverageEarnings ReportGap UpAVTEAerovate TherapeuticsN/A$6.89-4.2%N/A-87.8%$199.71MN/A-2.3020High Trading VolumeIPHAInnate Pharma2.2458 of 5 stars$2.15+1.9%$11.00+411.6%-0.5%$198.20M$21.77M0.00220Short Interest ↑SXTCChina SXT Pharmaceuticals0.4031 of 5 stars$1.70+9.0%N/A-80.8%$197.25M$1.93M0.0090Short Interest ↑Gap DownENGNenGene3.3552 of 5 stars$3.83+1.1%$23.29+508.0%-33.8%$195.73MN/A-2.3231Short Interest ↓GNFTGENFIT2.1616 of 5 stars$3.82-2.9%$13.00+240.8%+3.0%$190.01M$76.77M0.00120CTMXCytomX Therapeutics3.9802 of 5 stars$2.35+7.3%$5.75+144.7%+51.7%$189.46M$138.10M4.90170Trending NewsAnalyst RevisionEPRXEupraxia Pharmaceuticals1.9757 of 5 stars$5.30-1.8%$11.00+107.4%+102.3%$189.15MN/A-6.9829Positive NewsEarnings ReportVTYXVentyx Biosciences2.6506 of 5 stars$2.63-6.1%$10.00+280.2%+57.1%$187.15MN/A-1.5030TVGNSemper Paratus Acquisition3.7655 of 5 stars$1.00+1.1%$10.00+900.1%+35.2%$183.87MN/A0.003 Related Companies and Tools Related Companies MDWD Competitors AVTE Competitors IPHA Competitors SXTC Competitors ENGN Competitors GNFT Competitors CTMX Competitors EPRX Competitors VTYX Competitors TVGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KLRS) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access